Enveric Biosciences reported Q1 2026 net loss of $1.6 million with $1.08 loss per share, alongside EB-003 preclinical progress and $4.9 million cash position as of March 31, 2026.
Key takeaways
Net loss $1.6 million for Q1 2026, improved from $2.2 million in Q1 2025.
Diluted EPS loss $1.08 vs $14.58 prior year.
Cash $4.9 million at March 31, 2026; raised $2.8 million in offerings during quarter.
EB-003 preclinical data shows dual Gq/β-arrestin signaling at 5-HT2A for antidepressant effects.
AbbVie withdrew PGR petition against Enveric's U.S. Patent No. 12,138,276.
Post-quarter cash $10.3 million as of May 15, 2026, funding into Q1 2027.